Kiromic BioPharma, Inc. (KRBPQ)
OTCMKTS · Delayed Price · Currency is USD
0.0040
0.00 (0.00%)
Aug 15, 2025, 4:00 PM EDT
Kiromic BioPharma Employees
Kiromic BioPharma had 44 employees as of December 31, 2024. The number of employees increased by 9 or 25.71% compared to the previous year.
Employees
44
Change (1Y)
9
Growth (1Y)
25.71%
Revenue / Employee
n/a
Profits / Employee
-$105,136
Market Cap
6.28K
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 44 | 9 | 25.71% |
Dec 31, 2023 | 35 | 4 | 12.90% |
Dec 31, 2022 | 31 | -28 | -47.46% |
Dec 31, 2021 | 59 | 40 | 210.53% |
Dec 31, 2020 | 19 | 8 | 72.73% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 68 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
CytoDyn | 13 |
Silence Therapeutics | 116 |
Kiromic BioPharma News
- 6 months ago - Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival - Business Wire
- 7 months ago - Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01 - Business Wire
- 8 months ago - Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01 - Business Wire
- 9 months ago - Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation - Business Wire
- 9 months ago - SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews - Newsfile Corp
- 11 months ago - Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01 - Business Wire
- 11 months ago - Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial - Business Wire
- 11 months ago - Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial - Business Wire